Investigating The Mechanisms Underpinning The Dynamic Vessel Response In People With Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$18,808.00
Summary
Endothelial dysfunction has been well-hypothesised as one of the key players in the pathogenesis of DR. However, there is strong evidence suggesting a neurovascular coupling mechanism in the retinal circulation during flicker. It is therefore unclear whether reduced flicker light induced vasodilation observed in diabetes and DR is associated with endothelial dysfunction, an impairment of neurovascular coupling or both. This project aims to address this important knowledge gap.
Regulation Of ICAM-1 Expression In Human Retinal Endothelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$565,967.00
Summary
Posterior uveitis is an inflammation that occurs within the eye and may result in blindness. Present treatments are not directed specifically at the inflamed tissues, and they may be ineffective and cause toxicity. This research aims to identify molecules controlling the entry into the eye from the bloodstream of the white blood cells that cause the disease. The results should suggest new targets for safer drugs to treat patients with posterior uveitis.
The Influence Of Aqueous And Plasma Cytokines In Treatment Outcomes For Diabetic Macular Oedema
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Diabetic macular oedema (DME) is the commonest cause of central visual loss in diabetics and has been linked to increased levels of vascular endothelial growth factor (VEGF) in the eye. DME is treated with anti-VEGF injections, but these need to be repeated, with some patients failing to respond. We plan to see if levels of VEGF and other inflammatory markers will predict treatment response, so those unlikely to respond can be spared futile treatment and receive alternative treatment earlier.
Anti-vascular Endothelial Growth Factor-B As A Biologic For Treating Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$464,295.00
Summary
We plan to show that an engineered antibody fragment against vascular endothelial growth factor-B is an effective therapeutic drug for two eye diseases, corneal neovascularization and age-related macular degeneration. The innovative aspects of this approach are that it may be safer, and have a different spectrum of activity, than existing ophthalmic anti-angiogenic agents. Furthermore, it may be effective for corneal disease when administered as an eye-drop.
Mechanisms Of Retinal Functional Hyperaemia In Humans With And Without Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$117,526.00
Summary
Fenofibrate has been shown to reduce the progression of diabetic retinopathy (DR) in patients with type 2 diabetes by up to 40%, however the mechanisms behind this result are poorly understood. This research will investigate measures of local and systemic endothelial dysfunction and levels of lipids and lipoproteins to determine how fenofibrate affects the progression of DR in patients with type 2 diabetes and in doing so form the basis of further basic and clinical research.